PhotoCure
Hoffsveien 48
Oslo
0377
Tel: 47-22-06-22-10
Fax: 47-22-06-22-18
Website: http://www.photocure.com/
Email: vh@photocure.no
111 articles about PhotoCure
-
Photocure Partner Asieris announces positive international Phase III clinical trial results for Cevira and data presentations at the 2024 EUROGIN Congress and SGO Annual Meeting
3/18/2024
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated the Phase III clinical study results for its non-surgical treatment candidate for cervical high-grade squamous intraepithelial lesions Cevira®.
-
Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN
2/22/2024
Photocure ASA announces that its partner Asieris Pharmaceuticals has communicated that the international multicenter Phase III clinical study of Cevira®, the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions, will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia, held March 13-16 in Stockholm, Sweden:
-
Photocure ASA: Results for the fourth quarter of 2023
2/21/2024
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 114.2 million in the fourth quarter of 2023, an increase of 20% over the prior-year period, and EBITDA of NOK 29.9 million following solid business development for the Company.
-
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
11/29/2023
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals communicated that the National Medical Products Administration accepted the new drug application for Hexvix® in China.
-
Photocure to present at four investor conferences in November/December 2023
11/20/2023
Photocure ASA, The Bladder Cancer Company, announces its participation in four investor conferences focusing on the healthcare sector in Q4 2023:
-
Photocure ASA: Results for the third quarter of 2023
11/8/2023
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 107.3 million in the third quarter of 2023, and an EBITDA of NOK 3.3 million for the company.
-
Positive Results for Hexvix Phase III Clinical Trial in China Presented at the SIU 2023 Congress
10/12/2023
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has unveiled the results of its Hexvix® Phase III clinical trial in China.
-
Photocure ASA: Change of Board Composition
9/27/2023
Photocure, The Bladder Cancer Company, announces changes to the composition of its Board of Directors.
-
Photocure Partner Asieris announces that the First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint
9/20/2023
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated that the multinational Cevira® Phase III clinical trial has been completed and successfully met its primary endpoint.
-
Photocure ASA: Results for the second quarter and first half of 2023
8/9/2023
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 115.9 million in the second quarter of 2023, and an EBITDA of NOK 23.4 million.
-
Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China
7/6/2023
Photocure ASA, the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals has communicated that it has completed patient enrollment for the Hexvix® Phase III bridging trial.
-
Photocure ASA: Results for the first quarter of 2023
5/10/2023
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 105.9 million in the first quarter of 2023 and EBITDA of minus NOK 1.2 million.
-
Photocure ASA - Correction: Annual general meeting held - May 04, 2023
5/4/2023
Photocure ASA, held its annual general meeting on 3 May 2023 at 17:00 hours.
-
Photocure ASA: Invitation to presentation of first quarter 2023 financial results
5/3/2023
Photocure ASA will announce the first quarter 2023 financial results on Wednesday 10 May 2023 at 08:00 CEST and will present a live webcast at 14:00 CEST the same day.
-
Photocure: Nordic registry clinical data and multiple scientific programs at AUA 2023 Congress reinforce the benefits of Blue Light Cystoscopy
5/2/2023
Photocure ASA, the Bladder Cancer Company, announces that results from the Nordic Registry demonstrating benefits of Blue Light Cystoscopy were presented at the AUA 2023 Conference: the American Urological Association Annual Congress 2023 which was held April 28 - May 1, 2023 in Chicago, IL, USA.
-
Photocure: New data presented at EAU 2023 highlight the effects of blue light cystoscopy in bladder cancer
3/14/2023
Photocure ASA announces its participation in the congress, and two abstract presentations at the European Association of Urology congress in Milan, Italy, highlighting the benefits of Blue Light Cystoscopy in Bladder Cancer management.
-
Photocure ASA: Results for the fourth quarter of 2022
2/23/2023
Photocure ASA reported Hexvix®/Cysview® revenues of NOK 94.9 million in the fourth quarter of 2022, and an EBITDA of minus NOK 16.9 million.
-
Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC
2/20/2023
Photocure ASA, The Bladder Cancer Company, announces the presentation of clinical data from the Veterans Affairs BRAVO study at the ASCO Genitourinary Cancers Symposium which was held February 16-18, 2023 in San Francisco, USA.
-
New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement
1/3/2023
Photocure ASA, The Bladder Cancer Company, announces the publication of the study 'Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?' in Urologic Oncology this week.
-
New Evidence: Positive Impact of Blue Light Cystoscopy on Recurrence in Bladder Cancer Presented at the Annual SUO Meeting
12/5/2022
Photocure ASA, The Bladder Cancer Company, announces that new evidence was presented at the 22nd Annual Society of Urologic Oncology Meeting demonstrating that Blue Light Cystoscopy decreases the risk and prolongs time to recurrence based on Real World Evidence from the U.S. multi-institutional Blue Light Cystoscopy with Cysview® Registry database.